Head-to-head evidence
VRB-101 vs ZT006
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
VRB-101
Developed by Verdiva Bio
NCT07281937 · Phase 2 · completed
The trial randomly assigns participants to VRB-101 or a matching placebo and keeps participants, care providers and assessors all blinded, using percent body weight change, a standard measure for obesity drugs, as its main result. Results have not been posted yet, so whether the weight-loss difference was statistically meaningful is not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Next expected readout: November 2026 · NCT07553299 (registry estimate)
ZT006
Developed by Beijing QL Biopharmaceutical
NCT07307638 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled trial, but its primary endpoints are adverse-event rates rather than a weight-loss outcome, and no results have been posted yet, so its effect on body weight is unknown.
Next expected readout: December 2026 · NCT07230132 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: VRB-101's landscape · ZT006's landscape